Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)
26 sept. 2023 07h00 HE
|
Spinogenix, Inc.
Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat ALS
Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
12 sept. 2023 08h00 HE
|
Spinogenix, Inc.
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced a second...
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
10 juil. 2023 05h00 HE
|
Spinogenix, Inc.
SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it...
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
07 juin 2021 07h00 HE
|
Spinogenix, Inc.
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system disorders...
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
05 janv. 2021 05h00 HE
|
Spinogenix, Inc.
SAN DIEGO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced...
Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease
01 mai 2018 14h23 HE
|
Spinogenix, Inc.
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a preclinical stage, privately-held pharmaceutical company developing first-in-class drugs to reverse synapse loss and restore...
Medable Launches Synapse, a Fully Integrated Clinical Care App Platform Using CareKit
09 juin 2017 13h10 HE
|
Medable
PALO ALTO, Calif., June 09, 2017 (GLOBE NEWSWIRE) -- Medable Inc.--the leading app and analytics platform for healthcare--today announced the release of Synapse, the first cloud solution to enable...
Inc. Magazine Unveils 30th Annual List of America's Fastest-Growing Private Companies - the Inc. 500
31 août 2011 10h00 HE
|
Synapse Marketing Solutions
NEW YORK, Aug. 31, 2011 (GLOBE NEWSWIRE) -- NEW YORK, August 23, 2011 - Inc. magazine today ranked Synapse Marketing Solutions (Lancaster, PA) No. 396 on its 30th annual Inc. 500, an exclusive ranking...